Vaccination

Emergent BioSolutions Signs Agreement with Novavax to Manufacture NanoFlu™

Vaccines, Novavax, Emergent BioSolutions, Vaccination, Emergent, Medical specialties, Influenza vaccine, Vaccine, Health care, Medicine
Tuesday, March 31, 2020 - 9:05pm

GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will provide molecule-to-market contract development and manufacturing (CDMO) services to produce Novavaxs NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant.

Key Points: 
  • GAITHERSBURG, Md., March 31, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will provide molecule-to-market contract development and manufacturing (CDMO) services to produce Novavaxs NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant.
  • Novavax recently announced that NanoFlu met all primary objectives in its Phase 3 clinical trial evaluating immunogenicity and safety in adults aged 65 and older.
  • Emergent is pleased to expand our collaboration with Novavax to include large-scale production of NanoFlu, their novel influenza vaccine, said Syed T. Husain, SVP and CDMO business unit head at Emergent BioSolutions.
  • Under the terms of the agreement, Emergent will provide drug substance manufacturing services, including technology transfer and process validation and performance qualification to pave the way for commercial manufacturing.

BIOQUAL Announces COVID-19 Vaccine Testing

Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Infectious diseases, Other Health, Medical specialties, Medicine, Infectious diseases, Virology, RTT, Vaccination, Vaccine, Chikungunya, Nelson Michael, Marie-Paule Kieny
Tuesday, March 31, 2020 - 2:54pm

BIOQUAL announces the development of programs for in-vivo testing of COVID-19 candidate vaccines.

Key Points: 
  • BIOQUAL announces the development of programs for in-vivo testing of COVID-19 candidate vaccines.
  • For a number of years, BIOQUAL has been engaged in development of in-vivo testing programs and has been extensively involved in research efforts to develop vaccine and therapies against emerging diseases including AIDS, Hepatitis, Zika, Chikungunya and many others.
  • The company is now focused on COVID-19 research and is positioned to play an important role in the development of successful vaccines and therapies against this epidemic.
  • Statements herein that are not descriptions of historical facts are forward-looking and subject to risks and uncertainties.

Vaxart Provides Update on its Oral COVID-19 Vaccine Program

Vaccines, Medical specialties, Medicine, Health, Vaccination, Vaccine, Virology, Hypothetical technology, Herpes simplex research, H5N1 clinical trials
Tuesday, March 31, 2020 - 1:00pm

Each of the COVID-19 vaccine constructs is based on a different coronavirus antigen combination, and Vaxart expects to advance the best performing vaccine to manufacturing for clinical trials.

Key Points: 
  • Each of the COVID-19 vaccine constructs is based on a different coronavirus antigen combination, and Vaxart expects to advance the best performing vaccine to manufacturing for clinical trials.
  • Developing a vaccine to meet this current public health threat is very important to all of us at Vaxart, said Sean Tucker, Ph.D., chief scientific officer of Vaxart.
  • In January, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASTTM platform.
  • Vaxart is a clinical-stage biotechnology company primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform.

The Global Veterinary Clostridium Vaccine Market is expected to grow by USD 158.58 mn during 2020-2024, progressing at a CAGR of 5% during the forecast period

Microbiology, Microorganisms, Organisms, Vaccination, Vaccine, Virology, Clostridium, Marketplace
Monday, March 30, 2020 - 9:00pm

This study identifies inorganic growth strategies as the prime reasons driving the global veterinary clostridium vaccine market growth during the next few years.

Key Points: 
  • This study identifies inorganic growth strategies as the prime reasons driving the global veterinary clostridium vaccine market growth during the next few years.
  • The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
  • The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Detailed Insights on COVID-19 (Novel Coronavirus 19) - Identify Companies That Are Developing Therapies, Vaccines and Diagnostic Kits

Vaccination, Health, Pharmaceutical industry, Pharmacology, Pharmacy, Vaccine, Articles
Monday, March 30, 2020 - 5:00pm

Government agencies, Institutions, Biotech companies, pharmaceutical companies, around the world are working exhaustively and actively in finding a cure and are focused on developing vaccines/drugs to prevent or treat COVID-19infection.

Key Points: 
  • Government agencies, Institutions, Biotech companies, pharmaceutical companies, around the world are working exhaustively and actively in finding a cure and are focused on developing vaccines/drugs to prevent or treat COVID-19infection.
  • The recently launched report covers a detailed analysis of 50+ companies working for the development of drugs and vaccines as well as diagnostics companies are working on developing test kits.
  • Few other companies are learning from earlier vaccines from prior coronavirus outbreaks and making them more effective.
  • How many companies are developing therapies, vaccines and diagnostic kits for the treatment of COVID- 19?

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Virology, Vaccination, Vaccine
Monday, March 30, 2020 - 12:30pm

Johnson & Johnson will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts.

Key Points: 
  • Johnson & Johnson will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts.
  • We are very pleased to have identified a lead vaccine candidate from the constructs we have been working on since January.
  • Based on this work, Johnson & Johnson has identified a lead COVID-19 vaccine candidate (with two back-ups),which will progress into the first manufacturing steps.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Virology, Vaccination, Vaccine
Monday, March 30, 2020 - 12:22pm

Johnson & Johnson will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts.

Key Points: 
  • Johnson & Johnson will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts.
  • We are very pleased to have identified a lead vaccine candidate from the constructs we have been working on since January.
  • Based on this work, Johnson & Johnson has identified a lead COVID-19 vaccine candidate (with two back-ups),which will progress into the first manufacturing steps.
  • Copies of these filings are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.

Altimmune and the University of Alabama at Birmingham to Collaborate on Development of Single-Dose, Intranasal COVID-19 Vaccine

Medicine, Medical specialties, Vaccination, RTT, Vaccines, Virology, Influenza vaccines, Influenza vaccine, Biomedical Advanced Research and Development Authority, Vaccine, Influenza, Severe acute respiratory syndrome
Monday, March 30, 2020 - 12:00pm

Altimmune has significant experience in the development of intranasal vaccines for respiratory pathogens, including NasoVAX, a seasonal and pandemic influenza vaccine candidate, and NasoShield, a vaccine candidate for inhalation anthrax.

Key Points: 
  • Altimmune has significant experience in the development of intranasal vaccines for respiratory pathogens, including NasoVAX, a seasonal and pandemic influenza vaccine candidate, and NasoShield, a vaccine candidate for inhalation anthrax.
  • NasoShield is being developed under a $133.7 million contract with Biomedical Advanced Research and Development Authority (BARDA).
  • UAB has an impressive track record of cutting-edge research in virology and immunology, as well as in the clinical development of vaccines.
  • AdCOVID is a single-dose, intranasal vaccine candidate designed to protect against COVID-19, the disease caused by the SARS-CoV-2 virus.

Vaccitech to Present at Solebury Trout Virtual Investor Conference

Cancer, Viruses, Medicine, RTT, Coronaviridae, Vaccination, Infectious causes of cancer, Papillomavirus, Immunotherapy, Human papillomavirus infection, Coronavirus, Vaccine
Monday, March 30, 2020 - 10:00am

OXFORD, England, March 30, 2020 /PRNewswire/ -- Vaccitech Ltd , a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer,announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company's progress at the upcoming Solebury Trout Virtual Investor Conference.

Key Points: 
  • OXFORD, England, March 30, 2020 /PRNewswire/ -- Vaccitech Ltd , a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer,announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company's progress at the upcoming Solebury Trout Virtual Investor Conference.
  • Vaccitech is one ofthe fewcompanies in the world that has data in humans demonstrating neutralizing antibodies against a coronavirus withits MERS (Middle Eastern Respiratory Syndrome) vaccine candidate.
  • Vaccitech is a clinical stage T cell immunotherapy company developing treatments for cancer and infectious disease.
  • Vaccitech currently has a Phase 2a clinical programme for prostate cancer and is poised to enter the clinic with HPV and NSCLC therapeutics.

Vaccitech to Present at Solebury Trout Virtual Investor Conference

Cancer, Viruses, Medicine, RTT, Coronaviridae, Vaccination, Infectious causes of cancer, Papillomavirus, Immunotherapy, Human papillomavirus infection, Coronavirus, Vaccine
Monday, March 30, 2020 - 10:00am

OXFORD, England, March 30, 2020 /PRNewswire/ -- Vaccitech Ltd , a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer,announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company's progress at the upcoming Solebury Trout Virtual Investor Conference.

Key Points: 
  • OXFORD, England, March 30, 2020 /PRNewswire/ -- Vaccitech Ltd , a clinical stage biopharmaceutical company developing immunotherapies to treat infectious diseases and cancer,announced today that its Chief Executive Officer, Bill Enright, will present an update on the Company's progress at the upcoming Solebury Trout Virtual Investor Conference.
  • Vaccitech is one ofthe fewcompanies in the world that has data in humans demonstrating neutralizing antibodies against a coronavirus withits MERS (Middle Eastern Respiratory Syndrome) vaccine candidate.
  • Vaccitech is a clinical stage T cell immunotherapy company developing treatments for cancer and infectious disease.
  • Vaccitech currently has a Phase 2a clinical programme for prostate cancer and is poised to enter the clinic with HPV and NSCLC therapeutics.